Ipilimumab is a monoclonal antibody (mAb) targeting cytotoxic T-lymphocyte associated protein (CTLA-4), demonstrating increased lymphocyte counts and CD4+/CD8+ T cell percentages in melanoma patients correlated to improved survival (Martens et al., 2016). This evidence concerns the gene CTLA4 and melanoma.